Trokendi Xr

Migraine, Caloric Restriction, High cholesterol + 16 more

Treatment

20 Active Studies for Trokendi Xr

What is Trokendi Xr

Topiramate

The Generic name of this drug

Treatment Summary

Topiramate is an anticonvulsant medication used to treat seizures and prevent migraines. It was first approved by the FDA in 1996. In 2004, it was also approved for the prevention of migraines in adults. Since 2012, it has been approved in combination with phentermine to help adults manage their weight. It has a unique chemical structure and is made up of 40% oxygen. It was created when scientists were trying to create a new diabetes drug.

Topamax

is the brand name

image of different drug pills on a surface

Trokendi Xr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Topamax

Topiramate

1997

526

Effectiveness

How Trokendi Xr Affects Patients

Topiramate is used to prevent seizures and treat migraine symptoms by decreasing activity in the brain. It may cause dangerous side effects such as metabolic acidosis, mood changes, suicidal thoughts and attempts, and kidney stones. When taken with valproic acid, topiramate can also lead to hypothermia.

How Trokendi Xr works in the body

Seizures are caused by uncontrolled electrical activity in the brain. Topiramate works to reduce this activity in order to treat seizures and migraines. It does this by affecting GABA receptors, which normally inhibit nerve activity, and glutamate receptors, which stimulate activity. By increasing GABA activity and decreasing glutamate activity, topiramate blocks nerve signals from firing, preventing seizures and migraines. It also blocks voltage-dependent sodium channels in the brain, another way of reducing seizure activity. It is also known to affect certain carbonic anhydrase molecules, but we don't know what effect this has yet.

When to interrupt dosage

The prescribed measure of Trokendi Xr is contingent upon the diagnosed state, such as Seizures, Weight Reduction and Tonic - clonic seizures. The amount of dosage can be found in the table below, depending on the administration technique (e.g. Tablet, coated or Tablet).

Condition

Dosage

Administration

Alcoholism

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Obesity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Exercise

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Lennox Gastaut Syndrome

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Migraine

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Caloric Restriction

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

High cholesterol

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Obesity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

at least one weight-related comorbid condition

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Migraine Disorders

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Obesity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Seizures

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Type 2 Diabetes

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Hypertensive disease

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Epilepsy

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Weight Loss

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

increase in physical activity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Mood Disorders

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Chronic Weight Management therapy

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Capsule, extended release - Oral, Capsule, extended release, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Solution - Oral, Solution

Warnings

Trokendi Xr Contraindications

Condition

Risk Level

Notes

Acidosis

Do Not Combine

There are 20 known major drug interactions with Trokendi Xr.

Common Trokendi Xr Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Topiramate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Topiramate.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be increased when combined with Topiramate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Topiramate.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Topiramate.

Trokendi Xr Toxicity & Overdose Risk

Rats have been found to tolerate doses of up to 1500mg/kg of topiramate. In humans, overdosing on topiramate can cause symptoms ranging from mild to severe, such as low blood pressure, extreme acidosis, abdominal pain, seizures, confusion, dizziness, depression, and more. To treat an overdose, doctors may induce vomiting, give activated charcoal, or use dialysis.

image of a doctor in a lab doing drug, clinical research

Trokendi Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Trokendi Xr?

At present, there are 313 active trials investigating the potential of Trokendi Xr to address Type 2 Diabetes, Migraine and Exercise-associated conditions.

Condition

Clinical Trials

Trial Phases

Exercise

58 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Weight Loss

0 Actively Recruiting

Mood Disorders

0 Actively Recruiting

Migraine

51 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Obesity

0 Actively Recruiting

Chronic Weight Management therapy

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Seizures

5 Actively Recruiting

Phase 3, Phase 2, Phase 1

High cholesterol

0 Actively Recruiting

Obesity

0 Actively Recruiting

at least one weight-related comorbid condition

0 Actively Recruiting

Lennox Gastaut Syndrome

2 Actively Recruiting

Phase 1, Phase 2, Phase 4

Obesity

0 Actively Recruiting

Caloric Restriction

0 Actively Recruiting

Epilepsy

0 Actively Recruiting

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Type 2 Diabetes

162 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

increase in physical activity

0 Actively Recruiting

Trokendi Xr Reviews: What are patients saying about Trokendi Xr?

5

Patient Review

1/16/2020

Trokendi Xr for Migraine Prevention

I was 60 when I developed cluster headaches. tried Topamax regular and had the same side effects as others have described. My neuro switched me to the 25mg XR, and no more side effects, and about 1 cluster headache per year now.

4.7

Patient Review

11/13/2017

Trokendi Xr for Migraine Prevention

I've only had one migraine in the five months since I started this treatment, which is amazing because I was getting them two to three times a week previously. .25m at night does the trick for me with no negative side effects that I can tell.

4.3

Patient Review

1/10/2018

Trokendi Xr for Essential Tremor

Trokendi XR was recommended to me by my doctor, and I'm glad I gave it a try. After trying out different strengths, I found that the 50mg dosage worked best for me in terms of reducing hand shaking and other symptoms. The generic version didn't work as well for me, so be aware of that when you're considering this drug.

2.3

Patient Review

5/31/2018

Trokendi Xr for Migraine Prevention

At first, this medication seemed to help. I increased the dosage from 25mg to 50mg to 100mg. However, at 100mg I felt completely useless and bedridden. Tingling in my fingers and feet was a constant issue throughout the entire process. Now that I'm stopping the medication, I'm experiencing bone pain, tingling fingers and feet, frequent urination, back pain, and signs of kidney stones – all considered serious side effects.

1.7

Patient Review

11/29/2021

Trokendi Xr for Migraine Prevention

Dizziness, slurred speech, short term memory loss, no energy, loss of appetite, forgetful, frequent urination with incontence, hair breaking/ loss, very brittle finger / toe nails, increase headaches. These are just some of the issues I experienced while taking this medication. Please do not take it. I went cold turkey and after a bit more than two weeks felt so much better. Also able to start managing my life again.

1

Patient Review

5/12/2018

Trokendi Xr for Migraine Prevention

I have only been taking Trokendi for a short while, but it has already caused me serious problems. I started hallucinating a few hours after taking the medication, and it has made my speech slurred and walking difficult. I will be asking my neurologist to take me off this med as soon as possible. It also is not helping my migraines at all and has given me terrible acne.

1

Patient Review

1/10/2020

Trokendi Xr for Migraine Prevention

I was taking topiramate 25mg twice daily and it helped reduce my migraines to about 2-3 per month. However, when my neuro prescribed Trokendi XR at 25mg and then 50mg, my migraines came back with a vengeance. I'm going back on the topiramate soon if things don't improve.

1

Patient Review

5/10/2021

Trokendi Xr for Migraine Prevention

This medication was extremely dangerous and almost killed me. I lost 30 pounds as a result of taking it, and my BP plummeted to 53/30. I also developed neuropathy in both hands (which is now permanent) and suffered from fatigue, hair loss, and nail loss. This medication ruined my life and I would urge anyone considering taking it to avoid doing so at all costs.

1

Patient Review

9/10/2021

Trokendi Xr for Migraine Prevention

The side effects were really intense and debilitating. I felt constantly dizzy, my speech was slurred, and I had a lot of trouble concentrating or thinking clearly. On top of all that, I also experienced extreme anxiety. Luckily, I only lost 12 pounds in the two weeks that I took this medication.

1

Patient Review

4/15/2019

Trokendi Xr for Migraine Prevention

I had terrible side effects that began after only six weeks of taking the medication. I was constantly feeling low, exhausted, and anxious. If you have any history of mental illness or depression, I would not recommend this drug. It made me feel insane. Within two days of stopping the medication, most of the side effects dissipated. However, I still suffer from migraines on a daily basis.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about trokendi xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Trokendi XR make you sleepy?

"Trokendi may cause tiredness, sleepiness, drowsiness, dizziness, changes in vision, and slowed reactions. The use of alcohol with Trokendi may increase these side effects."

Answered by AI

What is Trokendi XR used for?

"Trokendi XR is a prescription medicine that is used to prevent migraines in adults and adolescents who are at least 12 years old. It is also used to treat certain types of seizures in people who are at least 6 years old."

Answered by AI

Is Trokendi XR the same as Topamax?

"Both drugs contain the same active ingredient called topiramate. Trokendi XR comes as an extended-release (long-acting) oral capsule and Topamax come as an immediate-release tablet or capsule. Trokendi XR is taken once a day, while Topamax is usually taken twice a day, in the morning and evening."

Answered by AI

Is Trokendi XR used for weight loss?

"While Trokendi XR is not approved as a weight loss medication, it is common for patients to lose weight while taking the drug, especially at higher doses. Your doctor may prescribe Trokendi XR off-label for binge eating disorder. If you have questions about Trokendi XR and weight loss, speak with your doctor."

Answered by AI

Clinical Trials for Trokendi Xr

Image of Faculty of Health Sciences in Winnipeg, Canada.

Saskatoon Berries for Type 2 Diabetes

18 - 74
All Sexes
Winnipeg, Canada

Diabetes becomes epidemic in worldwide countries. Diabetes Canada indicated that 30% of adults in Manitoba are diabetes or prediabetes. Nine out of ten diabetic patients are type 2 diabetes (T2D). T2D is characterized by insulin resistance and obesity. Uncontrolled diabetes leads to serious consequences including heart attack, stroke, chronic renal failure, liver failure, blindness and low limb amputation. Most of hypoglycemic medications have certain side effects. Natural foods or nutraceuticals with hypoglycemic potential are expected to provide a safer management for diabetic patients. Saskatoon berry is a popular fruit in Canadian Prairie and Northern states in USA. Our previous studies demonstrated Saskatoon berry (SB) powder attenuated hyperglycemia, hyperlipidemia, insulin resistance, inflammation, liver steatosis and gut dysbiosis in diet-induced insulin resistant mice, a model for T2D. The findings of the glucose and lipid lowering or liver protective effects of SB powder have been supported by another group in Australia in high fat fed rats. Our preliminary studies in 20 healthy subjects demonstrated that dried whole SB (40 g/day for 10 weeks) significantly reduced fasting plasma glucose, total and LDL-cholesterol, systolic blood pressure, and increased plasma glucagon-like peptide compared to baseline, which was associated with increased intake of total fiber and decreased intake of saturated fat. The changes in metabolic and vascular variables significantly correlated with the alterations in gut microbiota The combination of findings suggest that SB is good candidate of prebiotic functional food as a supplemental remedy for reducing the risk for metabolic syndrome and preventing or managing T2D. The effect of Saskatoon berry and its products on metabolic disorders have not been studied in diabetic subjects. We propose to examine the effects of oral administration of freeze-dried whole SB on glucose metabolism, insulin resistance and gut microbiota in untreated prediabetes and new type 2 diabetic patients compared to a control dried fruit in a randomized controlled trial.

Waitlist Available
New This Month

Faculty of Health Sciences

Image of Arkansas Children's Research Institute in Little Rock, United States.

We Move with Windy for Motor Skills

Any Age
All Sexes
Little Rock, AR

The long-term goal of this project is to learn whether a tailored physical activity program is practical, enjoyable, and helpful for families, and whether it has the potential to improve children's physical development and health. Before launching a large study, the research team completed several early phases to make sure the program met families' needs. First, a needs assessment was conducted with mothers to understand barriers to physical activity and what types of support would be most useful. Using this feedback, the program was refined and tested with three mother-child pairs over six weeks. Finally, there was an 18-week pilot randomized trial to examine feasibility and acceptability. Researchers are now conducting a larger randomized trial with up to 266 families. Half of the families are randomly assigned to receive the physical activity program, and half to a comparison group. The program combines fun, age-appropriate movement activities for children with practical support for parents. Sessions focus on building core movement skills such as jumping, balancing, running, and throwing, while also encouraging confidence, coordination, and enjoyment of being active. Activities can be adapted to each child's ability and home environment, making the program realistic for busy families. The program includes both in-person sessions and technology-based activities. In-person sessions provide hands-on support for learning new skills. Technology-based activities offer simple ideas families can use at home or during daily routines, such as hopping games, balance challenges, or quick movement breaks. Because parents in earlier phases wanted nutrition support, in-person sessions also includes a brief, child-friendly exposure to fruits and vegetables, along with simple recipes. A "Tasting Party" at the start of the program allows children to try different foods, and Veggie Meter scans at the beginning and end of the study help track changes in fruit and vegetable intake. Overall, this study will help determine whether a family-tailored physical activity program is a promising approach to improving physical activity, movement skills, and early health indicators in young children born to mothers with obesity.

Recruiting
Has No Placebo

Arkansas Children's Research Institute

Taren Swindle

Image of Arkansas Children's Research Institute in Little Rock, United States.

Exercise Program for Pregnant Women

18+
Female
Little Rock, AR

Regular physical activity during pregnancy is safe and offers many health benefits for both mothers and their babies. Research over the past decade shows that exercise can help pregnant women gain a healthy amount of weight, lower their risk of gestational diabetes and high blood pressure, and reduce stress, anxiety, and symptoms of postpartum depression. Babies also benefit when their mothers are active, with lower risks of preterm birth, unhealthy birth size, and childhood obesity. Despite this strong evidence, very few exercise programs for pregnant women have been tested in real-world community settings, such as fitness centers, community health programs, or local organizations. Even fewer studies explain how these programs were delivered or what helped them succeed. Without this information, it is difficult for communities and health programs to offer exercise support that is both effective and practical for pregnant women. To address this gap, the research team adapted an evidence-based program called EXPECTING so it could be delivered by community organizations. Previous participants and community advisors helped to understand what changes were needed to make the program easier to offer while still keeping it safe and effective. The core parts of the program, including the type, amount, and intensity of aerobic and strength-building exercises, remained the same and are based on established pregnancy exercise guidelines. The adapted program, called COMMUNITY EXPECTING, includes both aerobic exercise and resistance training. The research team also developed specific supports to help community instructors deliver the program consistently and with confidence. All program components have already been tested in community settings and shown to be realistic, acceptable, and delivered as planned. This study will examine whether offering a structured exercise program in community settings helps pregnant women be more physically active than usual prenatal care alone. We will also assess whether the program can be delivered successfully and in a way that works for both participants and community providers. The results will help determine whether COMMUNITY EXPECTING is a practical approach for supporting healthy pregnancies in real-world settings.

Recruiting
Has No Placebo

Arkansas Children's Research Institute

Taren Swindle

Have you considered Trokendi Xr clinical trials?

We made a collection of clinical trials featuring Trokendi Xr, we think they might fit your search criteria.
Go to Trials
Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Have you considered Trokendi Xr clinical trials?

We made a collection of clinical trials featuring Trokendi Xr, we think they might fit your search criteria.
Go to Trials
Image of Arizona State University in Phoenix, United States.

App-based Breathing Program for Migraine

18+
All Sexes
Phoenix, AZ

Migraine is one of the most common neurological disorders, characterized by recurrent headaches, sensitivity to light and movement, nausea, and autonomic dysregulation. Although mind-body interventions like biofeedback have shown their efficacy, they remain underutilized due to barriers such as transportation, time constraints, lack of awareness, stigma, and cost. A targeted approach to enhancing HRV is HRV biofeedback (HRVB), a technique using visual or auditory feedback to help people regulate HRV through slow-paced breathing and positive emotional regulation to promote ANS balance and emotional resilience. Investigators will conduct a remotely delivered pilot RCT of an 8-week, 10 min/day, novel app-based HRVB intervention compared to a sham control intervention (matching intervention time and attention with no biofeedback component) in adult with chronic migraine. Investigators hypothesize data collected from the study will: a) support the feasibility and acceptability of the remotely delivered app-based HRVB intervention among adults with chronic migraine, and b) provide insights into refining the intervention by examining patterns of change in migraine and psychological outcomes from pre- to post-intervention.

Waitlist Available
Online Trial

Arizona State University

Image of Human Performance Clinical Research Lab in Fort Collins, United States.

Virtual Exercise for Cancer

18+
All Sexes
Fort Collins, CO

The goal of this research study is to look at how live, online group exercise compares to recorded videos for helping increase physical activity levels, improve physical fitness and quality of life, and reduce loneliness among those living with and beyond cancer. The following aims have been established for this study: * Aim 1: Examine the effect of a group-based videoconference physical activity (PA) intervention on moderate to vigorous physical activity \[MVPA\] (i.e., aerobic and resistance exercise). * Aim 2: Examine the effect of the intervention on additional health-related outcomes including physical fitness (i.e., aerobic endurance, muscular strength), and quality of life at both timepoints. * Aim 3: Explore potential mediators and moderators of intervention effects. We will examine mediators (e.g., self-efficacy, outcome expectations, group cohesion) and moderators (e.g., age, cancer stage, neighborhood walkability) of the intervention on MVPA. * Exploratory Aim: Determine whether a group-based videoconference PA intervention reduces loneliness among cancer survivors. Researchers will randomize participants into one of two guided exercise groups that are 12-weeks long in duration. Participants will be asked to complete online fitness assessments and surveys as well as wear a physical activity monitor device and watch a few times throughout the study. The whole study is 9-months long in duration with a 6-month free-living period where no study activities will take place.

Recruiting
Has No Placebo

Human Performance Clinical Research Lab

Heather J Leach, PhD

Image of NYU Langone Health in New York, United States.

Adaptive Dietary Intervention for Type 2 Diabetes

18+
All Sexes
New York, NY

The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range \[TIR\] from baseline) will continue with the CGM alone during weeks 4-12 ("CGM Alone"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM ("CGM-GEM").

Waitlist Available
Has No Placebo

NYU Langone Health

Yaguang Zheng, PhD, RN

Have you considered Trokendi Xr clinical trials?

We made a collection of clinical trials featuring Trokendi Xr, we think they might fit your search criteria.
Go to Trials